11 November 2016

Pulmonary Circulation announcement

Impact Factor in 2017

Pulmonary Circulation’s first Impact Factor will be released in June 2017. Since its launch in 2011, our journal has become established as a unique venue of communication for clinical, translational and basic research in the fields of pulmonary circulation and pulmonary vascular disease. With a focus on translational science, Pulmonary Circulation connects researchers and physicians in all parts of the world. Articles published in the journal are set to make a major impact not only on future research, but also on improvement of health outcomes in our field.

Increasing impact and influence

A journal’s influence is indicated by its number of readers and our readership is growing at a staggering rate. Since launch, articles published in Pulmonary Circulation have been downloaded over half a million times, download numbers currently increasing by 50% each year. This is evidence that Pulmonary Circulation is seen as an increasingly important outlet for the most important research in pulmonary vascular disease.

Expanding Editorial Team

Our joint Editors in Chief, Dr Jason Yuan at University of Arizona, US, and Dr Nicholas Morrell, University of Cambridge, UK, reflect the international scope of the journal and the breadth of our scope across basic science and clinical research, and we welcome high quality articles on all aspects of pulmonary vascular disease. As our journal expands, we are delighted to announce the appointment of Dr Kurt Stenmark of the University of Colorado as deputy editor. Dr Stenmark has co-authored 275 publications and has expertise in paediatrics, high altitude, and right heart failure. His is the honored recipient of the 2015 Robert F. Grover prize from the American Thoracic Society and we are very pleased to welcome Dr Stenmark to the journal.

Partnership with SAGE Publishing

We are excited to be entering a partnership with SAGE Publishing in January 2017. SAGE is one of the world’s leading journal publishers and has 50 years of experience publishing journals in medicine, science, technology, social sciences, and the humanities. Pulmonary Circulation will benefit from increased global visibility, faster publication times, and SAGE's wealth of knowledge and commitment to scholarship and innovation. To submit manuscripts, click here for the SAGE submission system: https://mc.manuscriptcentral.com/pulmonarycirculation

Pulmonary Circulation goes online-only

After five years of publishing Pulmonary Circulation both in digital and print formats, the journal will become online-only from January 2017. As an open access journal publishing high quality research in an expanding field, the online format enables us to benefit from the latest developments in publishing technology without the limitations of print, and brings us into line with the standard format for open access journals. 

Author benefits

These changes bring a number of important benefits for our authors. We plan to reduce our reviewing times and also our production times after your article is accepted. Your published article will utilise cutting-edge technology to ensure maximum visibility and impact. And perhaps most importantly, publishing in Pulmonary Circulation allows your article to be immediately visible to the entire PVRI community - a global population of the world’s leading scientists and physicians studying the pulmonary circulation and pulmonary vascular disease.

We are pleased to provide access to translation and language editing services for authors to make use of before submitting their article. For a modest fee, the service can provide translation into English from Chinese, Portuguese, and Spanish. For authors whose article is already written in English and who wish to improve the grammar or language, stylistic editing and formatting services are also available.

Article processing charges

From 2011 to 2015, we published articles without any cost to our authors or to our readers. This provided an excellent benefit for our authors, whose articles were immediately available open access, worldwide, without any payment being made.

This has been possible due to grant funding support for the launch and establishment of the journal. We are now moving from being grant supported towards a self-sustaining model and we need to recover our costs of publishing the journal from the article processing charges (APCs). For two years our APCs have been very low in comparison with other open access journals at $1,000 for a research article and lower fees for other article types.

Publishing a journal is a labor-intensive endeavor and with our journal expanding it has not been possible to keep the APC so far below that of other journals. From 1 January 2017, we will be increasing the APC for research articles to $2,000. This will enable us to work towards a sustainable model and continue publishing the journal through the long term. We are pleased to say that the APC still remains considerably lower than the majority of open access journals in our field.

We want to take this opportunity to thank our authors, reviewers, associate editors, editorial board members, PVRI colleagues, publishers, and all others involved in producing Pulmonary Circulation.

We hope you will continue to submit your articles and we look forward to collaborating with you in the future.

We are entering into a new and exciting era for Pulmonary Circulation. We have a strong and committed Editorial Board, increasing submissions and citations, and this year we will receive our first Impact Factor. We are set to become the journal of choice for physicians and scientists in the pulmonary vascular field.
Dr Nicholas Morrell
I am very excited to work with SAGE, an internationally recognized publisher of scientific journals. Together, we will reach more readers and enhance the quality of Pulmonary Circulation. The journal is in good hands for future innovation, promotion and advancement.
Dr Jason Yuan

Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI